SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (3280)9/30/2002 5:32:02 PM
From: Icebrg  Read Replies (1) | Respond to of 10345
 
Bill

The really bad part is that assets that as recently as of June 29, 2002 nominally were valued at 148 mUSD only collected 6 mUSD when sold within a three-months period. Seen from that perspective the loss is mind-boggling. It raises serious questions with regard to the quality of assets still held in EPIL II and III.

Ice



To: William Partmann who wrote (3280)9/30/2002 5:32:09 PM
From: biostruggle  Read Replies (1) | Respond to of 10345
 
It is over. Even with zanaflex there is no way Elan can go from 375 mill to 200 million product revenue. There has to be hacky packy in the revenue recognition. Forget its over.

RIP


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News